Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol Acetate for Weight and QoL in Head and Neck Cancer
NCT00006799Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2000
- Primary completion
- Sep 2002
- Countries
- 1
- Sponsor
- Wake Forest University Health Sciences
- Modality
- Small Molecules
- Drugs
- megestrol
- Conditions
- anorexia nervosa (AN)cachexia
01
Overview
Phase 3, randomised, double-blind trial in anorexia nervosa (AN) and cachexia comparing Megestrol Acetate with Placebo (2 arms). Primary endpoint: Body Weight. Started Oct 2000; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Megestrol Acetate
Oral megestrol daily
Placebo
Oral placebo daily
03
Who it enrols
Patients with stage I-IV epithelial head and neck cancer scheduled for radiotherapy, ECOG 0-2, and no recent history of other malignancies or severe cardiovascular/metabolic conditions.
04
Endpoints
Primary
Body Weight
Secondary
Health-Related Quality of Life
Beyond the preview
Go deeper on NCT00006799.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006799.